PHARMACEUTICAL EQUIVALENCE ASSESSMENT OF YEMENI AND NON-YEMENI METFORMIN TABLETS MARKETED IN YEMEN
DOI:
https://doi.org/10.22159/ajpcr.2026v19i2.57262Keywords:
Metformin Hydrochloride, Quality Control of Tablet, Pharmaceutical Equivalence, YemenAbstract
Objectives: This study aimed to evaluate the pharmaceutical equivalence of Yemeni and Non-Yemeni metformin tablets marketed in Yemen by assessing key quality control parameters.
Methods: Both official USP and unofficial pharmacopeial tests were performed to assess weight uniformity, thickness, friability, hardness, disintegration, and dissolution. All experiments were conducted in triplicate, and results were expressed as mean ± standard deviation. Statistical comparisons between the two formulations were performed using Student’s independent t-test, with significance set at p < 0.05.
Results: Both formulations met USP specifications for weight, thickness, friability, disintegration, and dissolution. The hardness of Non-Yemeni tablets (19.2 ± 2.3 kg/cm²) was significantly higher than Yemeni tablets (11.6 ± 2.4 kg/cm²; p < 0.05), and both exceeded the recommended range for immediate-release tablets (4–8 kg/cm²). Disintegration times were within the pharmacopeial limit of 15 minutes, with Yemeni tablets disintegrating faster than Non-Yemeni tablets (p < 0.05). Dissolution efficiency was satisfactory for both products (>90%).
Conclusion: Both Yemeni and Non-Yemeni metformin tablets met USP quality standards across all evaluated parameters, confirming the pharmaceutical equivalence of Yemeni-manufactured and Non-Yemeni sourced metformin tablets.
Downloads
References
1. Grammatiki M, Sagar R, Ajjan RA. Metformin: Is it still the first line in type 2 diabetes management algorithm? Curr Pharm Des. 2021;27(8):1061-7. doi: 10.2174/1381612826666201222154616, PMID 33355048
2. Koffert JP, Mikkola K, Virtanen KA, Andersson AD, Faxius L, Hällsten K, et al. Metformin treatment significantly enhances intestinal glucose uptake in patients with type 2 diabetes: Results from a randomized clinical trial. Diabetes Res Clin Pract. 2017;131:208-16. doi: 10.1016/j.diabres.2017.07.015, PMID 28778047
3. Shurrab NT, Arafa ES. Metformin: A review of its therapeutic efficacy and adverse effects. Obes Med. 2020;17:100186. doi: 10.1016/j. obmed.2020.100186
4. Al Kamarany MA, Maad AH, Mohajab AA, Al-Masrafi I. Impact monitoring of low and high dexamethasone doses on COVID-19 outcomes in Al Hudaydah, Yemen: A pharmacoepidemiological study. Asian J Pharm Clin Res. 2025;18(1):52-5.
5. Alshargabi AR. In vitro assessment of physicochemical parameters of five generics amlodipine besylate tablets marketed in Yemen. Int J Pharm Pharm Sci. 2021;13(11):15-9. doi: 10.22159/ ijpps.2021v13i11.42898
6. Shi G, Lin L, Liu Y, Chen G, Luo Y, Wu Y, et al. Pharmaceutical application of multivariate modelling techniques: A review on the manufacturing of tablets. RSC Adv. 2021;11(14):8323-45. doi: 10.1039/D0RA08030F, PMID 35423324
7. Prakash G, Chandra SA, Sandhya P, Bidur C, Samir D. Pharmacopoeial comparison of in-process and finished product quality control test for pharmaceutical tablets. GSC Biol Pharm Sci. 2020;11(3):155-65. doi: 10.30574/gscbps.2020.11.3.0174
8. Wondmkun YT, Desta HK, Ali YS, Tsige AW, Ayenew KD, Endalifer BL, et al. In vitro comparative quality assessment of different brands of hydrochlorothiazide tablets marketed in Northeast Ethiopia. Front Anal Sci. 2024;4:1399843. doi: 10.3389/frans.2024.1399843
9. Abebe S, Ketema G, Kassahun H. In vitro comparative quality assessment of different brands of furosemide tablets marketed in Northwest Ethiopia. Drug Des Devel Ther. 2020;14:5119-28. doi: 10.2147/DDDT.S280203, PMID 33262573
10. Pharmacopeia U. United States Pharmacopeia and National Formulary (USP 37-NF 32). Rockville, MD: US Pharmacopeia; 2014.
11. Goh HP, Heng PW, Liew CV. Understanding effects of process parameters and forced feeding on die filling. Eur J Pharm Sci. 2018;122:105-15. doi: 10.1016/j.ejps.2018.06.026, PMID 29959985
12. Aulton ME, Taylor K, editors. Aulton’s Pharmaceutics: The Design and Manufacture of Medicines. Netherlands: Elsevier Health Sciences; 2013.
13. Markl D, Maclean N, Mann J, Williams H, Abbott A, Mead H, et al. Tablet disintegration performance: Effect of compression pressure and storage conditions on surface liquid absorption and swelling kinetics. Int J Pharm. 2021;601:120382. doi: 10.1016/j.ijpharm.2021.120382, PMID 33812971
14. Flatie Alemu A, Tegegne AA, Getaw NS. Evaluation of seven different brands of metformin hydrochloride tablets available in the market in Gondar City, Ethiopia. Drug Healthc Patient Saf. 2024;16:19-28. doi: 10.2147/DHPS.S419522, PMID 38318121
15. Momeni M, Afkanpour M, Rakhshani S, Mehrabian A, Tabesh H. A prediction model based on artificial intelligence techniques for disintegration time and hardness of fast disintegrating tablets in pre-formulation tests. BMC Med Inform Decis Mak. 2024;24(1):88. doi: 10.1186/s12911-024-02485-4, PMID 38539201
16. Sachdeva S, Singh H, Singh J. Enhancing dissolution and bioavailability: A review on co-processed superdisintegrants in pharmaceutical formulations. J Drug Deliv Ther. 2024;14(8):223-37. doi: 10.22270/ jddt.v14i8.6747
17. Hamdan II, Jaber AK. Pharmaceutical evaluation of metformin HCL products available in the Jordanian market. Jordan J Pharm Sci. 2010;3(22):1-7.
18. Ahmed Y, Maad AH, Hassan HA, Abdallah DB, Yousef M, Kadhum AA, et al. Evaluation of carboxymethyl millet starch and pregelatinized millet starch as pharmaceutical excipients using factorial experimental designs. Int J App Pharm. 2025;17(2):321-8. doi: 10.22159/ijap.2025v17i2.52161
19. Rashid N, Muhammad A, Abdul M, Muhammad N, Hassali K, Azmi M, et al. Formulation development of metformin tablet and its comparative in-vitro study with different brands in Pakistan. Int J Pharm Sci Rev Res. 2013;19:12-7.
20. Afifi SA, Ahmadeen S. A comparative study for evaluation of different brands of metformin hydrochloride 500 mg tablets marketed in Saudi Arabia. Life Sci J. 2012;9(4):4260-6.
Published
How to Cite
Issue
Section
Copyright (c) 2025 Abdullah H Maad, Tareq Maqlam, Bashir Ahmad Barashid
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.